O
CLVS

OrbiMed’s Clovis Oncology, Inc. CLVS Stock Holding History

OrbiMed’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,913,234
Closed -$28.4M – 142
2019
Q2 		$28.4M Sell
1,913,234
-919,066
-32% -$16.6M 0.44% 55
2019
Q1 		$70.3M Buy
2,832,300
+80,100
+3% +$2.01M 1.09% 29
2018
Q4 		$49.4M Buy
2,752,200
+517,630
+23% +$10.6M 0.91% 37
2018
Q3 		$65.6M Sell
2,234,570
-96,300
-4% -$3.73M 0.79% 39
2018
Q2 		$106M Hold
2,330,870
– – 1.26% 26
2018
Q1 		$123M Buy
2,330,870
+359,200
+18% +$21M 1.53% 19
2017
Q4 		$134M Sell
1,971,670
-417,000
-17% -$29.2M 1.7% 18
2017
Q3 		$197M Buy
2,388,670
+284,300
+14% +$22.5M 1.88% 15
2017
Q2 		$197M Buy
+2,104,370
New +$129M 2.07% 16
2016
Q2 		– Sell
-660,900
Closed -$12.7M – 146
2016
Q1 		$12.7M Sell
660,900
-68,700
-9% -$1.45M 0.13% 80
2015
Q4 		$25.5M Sell
729,600
-376,300
-34% -$24.3M 0.23% 68
2015
Q3 		$102M Buy
1,105,900
+100,700
+10% +$8.71M 1.03% 35
2015
Q2 		$88.3M Buy
1,005,200
+4,800
+0.5% +$411K 0.74% 40
2015
Q1 		$74.3M Buy
1,000,400
+286,300
+40% +$20.2M 0.63% 45
2014
Q4 		$40M Buy
+714,100
New +$37.5M 0.38% 56

Other funds holding CLVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

OrbiMed's CLVS Position: Q3 2019 in Review

OrbiMed sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 1,913,234 shares — an estimated $28.4M sold.

OrbiMed first reported a position in CLVS in Q4 2014 and held it in 15 quarters. The position peaked at $197M in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

  • OrbiMed reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
  • OrbiMed sold 1,913,234 Clovis Oncology, Inc. shares in Q3 2019, an estimated $28.4M.
  • OrbiMed first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 15 quarters.
  • OrbiMed's Clovis Oncology, Inc. position peaked at $197M in Q2 2017.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.